Gyre Therapeutics (NASDAQ:GYRE) Trading 9% Higher – Still a Buy?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s stock price traded up 9% during mid-day trading on Thursday . The stock traded as high as $7.13 and last traded at $7.1050. 47,569 shares were traded during mid-day trading, a decline of 50% from the average daily volume of 95,853 shares. The stock had previously closed at $6.52.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on the company. Weiss Ratings downgraded Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Wall Street Zen lowered shares of Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Finally, Zacks Research cut Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research report on Monday, March 16th. Two analysts have rated the stock with a Buy rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat, Gyre Therapeutics presently has a consensus rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Stock Up 9.4%

The company has a 50-day moving average of $6.55 and a 200 day moving average of $7.26. The firm has a market capitalization of $794.92 million, a PE ratio of -79.24 and a beta of 1.90.

Insiders Place Their Bets

In other news, COO Weiguo Ye sold 12,820 shares of the firm’s stock in a transaction on Thursday, May 21st. The shares were sold at an average price of $6.15, for a total transaction of $78,843.00. Following the sale, the chief operating officer owned 700,000 shares in the company, valued at approximately $4,305,000. This trade represents a 1.80% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Ying Luo sold 10,136 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total value of $81,493.44. Following the sale, the chief executive officer owned 2,565,226 shares in the company, valued at $20,624,417.04. The trade was a 0.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 32,535 shares of company stock worth $219,580 in the last three months. Insiders own 9.50% of the company’s stock.

Institutional Investors Weigh In On Gyre Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of GYRE. Bank of America Corp DE raised its holdings in Gyre Therapeutics by 40.4% during the 4th quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after buying an additional 1,996 shares during the last quarter. Geode Capital Management LLC increased its position in Gyre Therapeutics by 28.6% during the 2nd quarter. Geode Capital Management LLC now owns 401,709 shares of the company’s stock valued at $2,953,000 after buying an additional 89,390 shares in the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after acquiring an additional 2,961 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in Gyre Therapeutics by 77.8% in the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after buying an additional 3,244 shares during the last quarter. Finally, Lazard Asset Management LLC purchased a new position in Gyre Therapeutics in the 3rd quarter worth approximately $111,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.